Website: Metcela
Business Area(s):
Description:
Metcela’s core patented technology involves a particular population of cardiac fibroblasts, namely VCAM-1-positive cardiac fibroblast (VCF)*. VCAM-1-positive cardiac fibroblasts are known to replenish and re-establish the damaged cardiac muscles and the microenvironment surrounding them.
Location(s):
Yamagata
Japan
See map: Google Maps